151 related articles for article (PubMed ID: 23687785)
1. HER2-directed treatment of metastatic breast cancer: unanswered questions.
Rao R; Cobleigh M
Oncology (Williston Park); 2013 Mar; 27(3):176, 178, 180. PubMed ID: 23687785
[No Abstract] [Full Text] [Related]
2. How can we optimize treatment of HER2-positive metastatic breast cancer?
Hamilton EP; Blackwell KL
Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
[No Abstract] [Full Text] [Related]
3. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
4. Next-generation targeted agents in HER2-positive metastatic breast cancer.
Perez EA
Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
[No Abstract] [Full Text] [Related]
5. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
Janjigian YY; Braghiroli MI
Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
7. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right..
Jankowitz RC; Rastogi P
Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152
[No Abstract] [Full Text] [Related]
8. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
9. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Abair T; O'Shaughnessy J
Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
[No Abstract] [Full Text] [Related]
12. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
13. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Nahta R
Expert Opin Biol Ther; 2013 Jul; 13(7):949-52. PubMed ID: 23565676
[TBL] [Abstract][Full Text] [Related]
15. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
16. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Campone M; Frenel JS; André F; Bachelot T; Juin P
Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
18. New research on the treatment of small HER2-positive breast cancers.
Krop IE
Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
[No Abstract] [Full Text] [Related]
19. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
O'Sullivan CC; Connolly RM
Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
[TBL] [Abstract][Full Text] [Related]
20. Targeting the HER2 receptor in metastatic breast cancer.
Orphanos G; Kountourakis P
Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
